LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Manufacturing Facility
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • IR Inquiries
U.S. Embassy made an industrial observation trip to MEDIPOST cord blood facilities etc.
2015/08/17
CORD BLOOD BANK

Industrial observation group from U.S. Embassy in Korea visited MEDIPOST headquarters in Pangyo on August 13.

The observation group toured the MEDIPOST stem cell exhibition hall, cord blood storage and research facilities etc. and had discussion with MEDIPOST staffs.

Especially they showed big interest on overseas clinical trial status of stem cell medicines, and treatment case of disease using cord blood etc.

In this regard, the staff from MEDIPOST mentioned that “The visit was a direct opportunity to show the high technological level of domestic stem cell and cord blood industry”.

Meanwhile, the Economic Department of U.S. Embassy in Korea started tour of major domestic corporates to expand their understanding on the industrial site, since this month. In biological sector, MEDIPOST was the only destination.

VIEW LIST

Related News

MEDIPOST starts cord blood-derived immune cell therapy development with the establishment of its subsidiary “IMMUNIQUE”2021/04/02
Star Actress Choi Jiwoo Stores Her Baby’s Umbilical Cord Blood Unit at MEDIPOST’s CELLTREE2020/05/18
Longer-Term Storage of Cord Blood Gains Popularity Over 20,000 Cumulative Cases at CELLTREE2020/04/29
Korean Star Couple Rain and Kim Tae-hee Bank Baby’s Cord Blood in MEDIPOST2017/10/25

Latest News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.
2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge
2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy
2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award
2022/07/18
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products
2022/05/31

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

CS CENTER
ONLINE INQUIRY

Latest News

·
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022.12.01
·
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022.10.17
·
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022.10.07
·
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022.07.18
·
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022.05.31

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST